Pompe Disease Treatment Market Analysis, Demand Overview and Forecast till 2025

Posted by Shrikant Gadewar on December 5th, 2019

Market Highlights:

The global Pompe Disease Treatment Market is estimated to be valued at USD 1,414.1 million by 2025 and is expected to register a CAGR of 2.6% during the forecast period.

Pompe disease is a disorder affecting almost 1 in 40,000 people in the US. Factors such as constant uptake of long-term therapies, high cost of treatment, and launch of novel drugs are boosting the market growth. It is an autosomal recessive glycogen storage disorder and occurs due to deficiency of lysosomal enzyme acid α-glucosidase (GAA). The juvenile or adult-onset form and is reported to be the most common form in almost 80% of patients. This disorder primarily affects cardiac and skeletal muscle and manifests as progressive respiratory distress, skeletal muscles atrophy, and cardiomyopathy.

Access Full Report Details and TOC Exclusively @ https://www.marketresearchfuture.com/reports/pompe-disease-treatment-market-8233

Major Players:

•          Audentes Therapeutics
•          CENTOGENE AG
•          Oxyrane
•          Amicus Therapeutics
•          Genzyme Corporation
•          Valerion Therapeutics
•          AVROBIO

Segment Analysis

•          The global Pompe disease treatment market by type has been segmented into onset Pompe disease, non-classic infantile-onset Pompe disease, and classic infantile-onset Pompe disease. Late-onset Pompe disease, a heterogeneous form of the disease, causes various problems related to musculoskeletal, neuromuscular, respiratory, and cardiac functioning. Late-onset Pompe disease mainly appears during teenage or adulthood.
•          The treatment of Pompe disease is disease-specific and depends on the symptoms of the disease. The global Pompe disease treatment market on the basis of therapy has been divided into, enzyme replacement therapy (ERT), gene therapy, and others. The enzyme replacement therapy (ERT) segment captures the maximum share of the total market as it is the only Food and Drug Administration (FDA) approved therapy for the treatment of Pompe diseases.
•          The Pompe disease treatment market has been classified, on the basis of end user, as hospitals & clinics and research & academic institutes.

Regional Analysis

The global Pompe disease treatment market, based on region, has been categorized as the Americas, Europe, Asia-Pacific, and the Middle East & Africa.

American regions are hubs for major market players operating in the Pompe disease treatment market, which eventually drives the growth of the American Pompe disease treatment market. Additionally, the rising awareness among the public about the available treatments for Pompe disease is projected to boost the market growth in America during the forecast period.

Europe stands second in the global Pompe disease treatment market followed by Asia-Pacific. European countries are extremely cautious and have implemented the new-born screening (NBS) program as a means of early detection and identification of severe illnesses in new-borns.